Please login to the form below

Not currently logged in
Email:
Password:

10 Years of EU Orphan Drug Regulation

The European Medicines Agency is marking the 10th anniversary of orphan drug regulation implementation in Europe with a conference and workshops

It is 10 years since orphan drug regulation was implemented in Europe and the European Medicines Agency (EMA) is marking the anniversary with various conferences and workshops during April and May.

In April 2000, Regulation (EC) No 141/2000 of the European Parliament and the Council on Orphan Medicinal Products came into effect. Since then, over 700 products have received orphan designation to treat rare disorders.

The regulation established the criteria for orphan designation in the EU and delineated the incentives, including market exclusivity, protocol assistance, and access to the centralised procedure for marketing authorisation. The regulation was also developed to encourage the research, development and marketing of medicines to treat, diagnose or prevent rare diseases.    

Two workshops and a conference are scheduled to take place at EMA headquarters in London. The first workshop, on nanomedicines, is scheduled for April 26-27, and the second, on May 10, will focus on stem cell-based therapies. 

Then on May 3-4 there will be a conference, entitled 10 Years of the Orphan Regulation in Europe, featuring plenary sessions, discussions and three parallel workshops on the development of products for rare diseases, research for rare diseases and patients' views on the Regulation. 

Further details are available from the EMA

24th March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics